Next Article in Journal
Thoracic Epidural Analgesia in Major Cancer Surgery: An Update
Previous Article in Journal
Family Tree Mapping of Genetic and Phenotypic Codes of Hereditary Angioedema
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis

by
Jurairat Jongthawin
1,2,
Wanlaya Naowaratwattana
1,
Jongkonnee Thanasai
1,
Darunee Puangpronpitag
1,3,
Hasaya Dokduang
1,2,
Issarapong Phosuk
4 and
Wipavadee Daiponmak
1,*
1
Faculty of Medicine, Mahasarakham University, Maha Sarakham 44000, Thailand
2
Biomedical Science Research Unit, Mahasarakham University, Maha Sarakham 44000, Thailand
3
International and National Collaborative Network and Innovation for Community Health Development Research Unit, Mahasarakham University, Maha Sarakham 44000, Thailand
4
Department of Public Health, Amnatcharoen Campus, Mahidol University, Amnat Charoen 37000, Thailand
*
Author to whom correspondence should be addressed.
Medicina 2026, 62(9), 1636; https://doi.org/10.3390/medicina62091636
Submission received: 14 July 2026 / Revised: 21 August 2026 / Accepted: 24 August 2026 / Published: 26 August 2026
(This article belongs to the Section Genetics and Molecular Medicine)

Abstract

Background and Objectives: Hereditary medullary thyroid carcinoma (hMTC) exhibits substantial clinical heterogeneity according to the underlying germline RET pathogenic variant. Although the germline RET M918T pathogenic variant is associated with aggressive disease, its associations with clinical outcomes have not been comprehensively quantified. We aimed to evaluate the associations between the M918T variant and adverse clinical outcomes in patients with hMTC. Materials and Methods: PubMed, Scopus, and Embase were searched from database inception to May 2026 in accordance with PRISMA 2020. Eligible studies compared patients with the germline RET M918T pathogenic variant with those harboring other germline RET pathogenic variants. Random-effects models were used to pool odds ratios (ORs) and 95% confidence intervals (CIs) for lymph node metastasis, metastatic disease, advanced-stage disease, and mortality. Risk of bias was assessed using the Quality in Prognosis Studies tool. The protocol was prospectively registered in PROSPERO (CRD420261377120). Results: Nine cohort studies involving 1485 participants were included, with outcome-specific sample sizes varying. Three studies had a low overall risk of bias and six had a moderate risk. The M918T variant was associated with increased odds of lymph node metastasis (OR 7.86, 95% CI 2.58–23.94), metastatic disease (OR 6.50, 95% CI 3.72–11.37), advanced-stage disease (OR 4.88, 95% CI 2.30–10.33), and mortality (OR 7.32, 95% CI 3.14–17.10). The association was stronger for disease-specific than all-cause mortality, although the subgroup difference was not statistically significant. Conclusions: The germline RET M918T pathogenic variant was associated with adverse clinical outcomes compared with other germline RET pathogenic variants. However, heterogeneous comparator groups and residual confounding preclude causal interpretation.
Keywords: germline RET M918T pathogenic variant; hereditary medullary thyroid carcinoma; lymph node metastasis; metastatic disease; prognosis; systematic review; meta-analysis germline RET M918T pathogenic variant; hereditary medullary thyroid carcinoma; lymph node metastasis; metastatic disease; prognosis; systematic review; meta-analysis

Share and Cite

MDPI and ACS Style

Jongthawin, J.; Naowaratwattana, W.; Thanasai, J.; Puangpronpitag, D.; Dokduang, H.; Phosuk, I.; Daiponmak, W. Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Medicina 2026, 62, 1636. https://doi.org/10.3390/medicina62091636

AMA Style

Jongthawin J, Naowaratwattana W, Thanasai J, Puangpronpitag D, Dokduang H, Phosuk I, Daiponmak W. Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Medicina. 2026; 62(9):1636. https://doi.org/10.3390/medicina62091636

Chicago/Turabian Style

Jongthawin, Jurairat, Wanlaya Naowaratwattana, Jongkonnee Thanasai, Darunee Puangpronpitag, Hasaya Dokduang, Issarapong Phosuk, and Wipavadee Daiponmak. 2026. "Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis" Medicina 62, no. 9: 1636. https://doi.org/10.3390/medicina62091636

APA Style

Jongthawin, J., Naowaratwattana, W., Thanasai, J., Puangpronpitag, D., Dokduang, H., Phosuk, I., & Daiponmak, W. (2026). Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Medicina, 62(9), 1636. https://doi.org/10.3390/medicina62091636

Article Metrics

Back to TopTop